Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
GENTAK vs LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Loteprednol etabonate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
1-2 drops into affected eye(s) every 4-6 hours; in severe cases, may be given every 1-2 hours initially.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Loteprednol etabonate: ~2.8 hours (ocular); Tobramycin: ~2-3 hours (systemic, prolonged in renal impairment)
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Loteprednol etabonate: 75% renal, 20% fecal; Tobramycin: >90% renal as unchanged drug via glomerular filtration
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic